Codexis appoints H. Stewart Parker to Board of Directors

CODEXIS, INC.

H. Stewart Parker appointed as Class II director, term expiring at 2024 annual meeting.
Appointed to Audit Committee and Strategic Committee; Board determined independent.
Parker will receive annual cash retainer of $50,000, plus $20,000 Audit and $10,000 Strategic committee retainers.
Granted 37,878 restricted stock units vesting over three years; future annual grants of $100,000 in RSUs.
Parker brings biopharma leadership experience; currently on boards of IMPEL Pharmaceuticals and Sangamo Therapeutics.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

H. Stewart Parker

Director

CDXS · CODEXIS, INC.

Effective: 2022-12-16
Filed: December 20, 2022, 6:59 PM ET

On December 16, 2022, the Board of Directors (the “Board”) of Codexis, Inc. (the “Company”) appointed H. Stewart Parker as a member of the Board as a Class II director with an initial term expiring at the Company’s 2024 annual meeting of stockholders.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

H. Stewart Parker was appointed as Director at CODEXIS, INC..

Action: appointed
Role: Director

Exact text from the filing

On December 16, 2022, the Board of Directors (the “Board”) of Codexis, Inc. (the “Company”) appointed H. Stewart Parker as a member of the Board as a Class II director with an initial term expiring at the Company’s 2024 annual meeting of stockholders.

View on SEC.gov

CODEXIS, INC. filing history →

Source: SEC EDGAR

accession 0001193125-22-309175

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.